Stockreport
BioMarin Pharmaceutical Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year [Yahoo! Finance]
Last biomarin pharmaceutical inc. earnings: 4/29 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations: investors.biomarin.com
The early response was not positive, with shares down 8.2% to US$82.13 in the past week. Revenues were US$649m, approximately in line with whatthe analysts expected, although statutory earnings per share (EPS) crushed expectations, coming in at US$0.46, an impressive 41% ahead of estimates. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. We've gathered the most recent statutory forecasts to see whether the analysts have changed their earnings models, following these results. Check out our latest analysis for BioMarin Pharmaceutical Taking into account the latest results, the consensus forecast from BioMarin Pharmaceutical's 28 analysts is for revenues of US$2.74b in 2024. This reflects a solid 11% improvement in revenue compared to the last 12 months. Per-share earnings are expected to shoot up 68% to US$1.81.
[Read more]
IMPACT SNAPSHOT | EVENT TIME: | BMRN | ||||
---|---|---|---|---|---|---|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
LAST PRICE | ||
VWAP | ||
High:
|
MAX UP |
High:
|
Low:
|
MAX DOWN |
Low:
|
%
|
POST NEWS RANGE |
%
|
|
PRICE CHANGE |
|
|
PRICE CHANGE PERCENTAGE |
|
|
S&P 500 (SPX) |
|
%
|
VOLUME RATIO |
%
|
VOLUME (SHARES) | ||
TICKS | ||
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
BMRN alerts
BMRN alerts
from News Quantified
Movers & Shakers
The biggest gainers and losers and WHY it moved
BMRN alerts
High impacting BioMarin Pharmaceutical Inc. news events
Weekly update
A roundup of the hottest topics
BMRN
NEWS
NEWS
- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) was downgraded by analysts at Robert W. Baird from an "outperform" rating to a "neutral" rating. They now have a $72.00 price target on the stock, down previously from $104.00.[MarketBeat]
- BioMarin Pharmaceutical to lay off 170 employees [Seeking Alpha][Seeking Alpha]
- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) is now covered by analysts at Evercore ISI. They set an "outperform" rating and a $113.00 price target on the stock.[MarketBeat]
- BioMarin to Present at the BofA Securities 2024 Health Care Conference on Wednesday, May 15 at 10:00am PT / 1:00pm ET, in Las Vegas, NV [Yahoo! Finance][Yahoo! Finance]
- BioMarin to Present at the BofA Securities 2024 Health Care Conference on Wednesday, May 15 at 10:00am PT / 1:00pm ET, in Las Vegas, NV[PR Newswire]
- More
BMRN
SEC Filings
SEC Filings
- 5/14/24 - Form 8-K
- 5/13/24 - Form 4
- 5/10/24 - Form 144
- BMRN's page on the SEC website
- More